Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-TTRSC02 in Healthy Subjects
NCT02797847Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Jan 2018
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Transthyretin amyloidosis (ATTR) comparing ALN-TTRSC02 with Placebo (2 arms). Primary endpoint: Proportion of subjects experiencing adverse events at Day 314. Started Jun 2016; status: completed.
02
Drugs
vutrisiran
03
Conditions
Transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT02797847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797847.